Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
NCT ID: NCT01159249
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
245 participants
INTERVENTIONAL
2010-06-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
NCT00325429
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
NCT00389415
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
NCT01497522
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
NCT01582230
To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
NCT00325117
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Met add-on vildagliptin
Vildagliptin
Open TZD add-on vildagliptin
Vildagliptin
Open α-GI add-on vildagliptin
Vildagliptin
Glinides add-on vildagliptin
Vildagliptin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vildagliptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age in the 20 years or over inclusive
* HbA1c in the range of ≥ 6.5 to ≤ 10%
Exclusion Criteria
* Significant heart diseases
* Significant diabetic complications
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals Corporation
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Hunabashi, Chiba, Japan
Novartis Investigative Site
Chikushino-shi, Fukuoka, Japan
Novartis Investigative Site
Itoshima-shi, Fukuoka, Japan
Novartis Investigative Site
Kōriyama, Fukushima, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Izumisano, Osaka, Japan
Novartis Investigative Site
Hannou, Saitama, Japan
Novartis Investigative Site
Hiki-Gun, Saitama, Japan
Novartis Investigative Site
Kawaguchi, Saitama, Japan
Novartis Investigative Site
Koshigaya, Saitama, Japan
Novartis Investigative Site
Tokorozawa, Saitama, Japan
Novartis Investigative Site
Edogawa-ku, Tokyo, Japan
Novartis Investigative Site
Hachiōji, Tokyo, Japan
Novartis Investigative Site
Katsushika-ku, Tokyo, Japan
Novartis Investigative Site
Minato-ku, Tokyo, Japan
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan
Novartis Investigative Site
Toshima-ku, Tokyo, Japan
Novartis Investigative Site
Fukuoka, , Japan
Novartis Investigative Site
Fukuoka, , Japan
Novartis Investigative Site
Fukuoka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CLAF237A1308 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLAF237A1308
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.